All In Biotech

Drug Trial Radar · NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 15, 2025

Primary completion

Jan 2029

Study completion Dec 1, 2037

Sponsor

Lead sponsor
St. Olavs HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Norwegian University of Science and Technology; Haukeland University Hospital; Helse Stavanger HF; Oslo University Hospital; University Hospital, Akershus; Sykehuset i Vestfold Hospital Trust; University Hospital of North Norway; Ålesund Hospital, Norway; Helse Nord-Trøndelag HF; Sorlandet Hospital HF; Førde Hospital Trust; Molde Hospital; Bodø Hospital, Norway; Helse Fonna; Volda Hospital; Diakonhjemmet Hospital; Telemark Hospital Trust; Kristiansund Hospital; Vestre Viken Hospital Trust; Lovisenberg Diakonale Hospital; Sykehuset Innlandet HF
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Conditions

  • Myeloma Multiple
  • Plasma Cell Leukemia
  • AL Amyloidosis

Interventions

  • TeclistamabDrug

    Real-world use and dosing

  • ElranatamabDrug

    Real-world use and dosing

  • Ciltacabtagene AutoleucelBiological

    Real-world use.

  • TalquetamabDrug

    Real-world use and dosing

  • Idecabtagene vicleucelBiological

    Real-world use and dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the real-world overall response rates (ORR)Time frame: From date of treatment start and until date of first documented progression or start of next line of therapy, whichever came first, assessed up to ten years.
  2. Determine real-world progression-free survival (PFS)Time frame: From date of treatment start and until date of first documented progression or death, whichever came first, , assessed up to ten years.
  3. Determine real-world time-to-next treatment (TTNT)Time frame: From date of treatment start and until date of start of next treatment, assessed up to ten years.
  4. Determine real-world overall survival (OS)Time frame: From date of treatment start and until death, assessed up to ten years.
  5. Describe the frequency and grading of adverse events of special interest (AESI), defined as described below.Time frame: From date of treatment start until the date of start of next line of treatment or death, whichever came first, assessed up to 10 years
  6. Frequency and grading of all other adverse events occurring during treatment according to CTCAE 5.0 (only grade 3 or higher will be reported).Time frame: From start of treatment and until start of next treatment or death, assessed up to ten years.
  7. Describe the microbiological pattern (positive cultures/PCR) of infections during treatment.Time frame: From start of treatment and start of next treatment line or death, assessed up to ten years.
  8. Describe the antibiotic resistance pattern of positive cultures.Time frame: From start of treatment and start of next treatment line or death, assessed up to ten years.
  9. Describe the prevalence of common airway viruses during treatment and at end-of-treatment.Time frame: From date of start of treatment and until end of treatment, assessed up to ten years.
  10. Determine the real-world use of antimicrobial prophylaxis (antibiotics, antivirals, vaccines, immunoglobulines) before and during therapy.Time frame: From enrollment and until end of treatment, assessed up to ten years.

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Ålesund hospital, Department of hematology

    Ålesund, Norway · Not yet recruiting

  • Sørlandet Hospital - Arendal

    Arendal, Norway · Not yet recruiting

  • Bærum Hospital

    Bærum, Norway · Not yet recruiting

  • Haukeland University Hospital

    Bergen, Norway · Not yet recruiting

  • Bodø Hospital

    Bodø, Norway · Not yet recruiting

  • Drammen hospital

    Drammen, Norway · Not yet recruiting

  • Førde hospital

    Førde, Norway · Not yet recruiting

  • Innlandet hospital trust

    Gjøvik, Norway · Not yet recruiting

  • Haugesund hospital

    Haugesund, Norway · Not yet recruiting

  • Sørlandet hospital

    Kristiansand, Norway · Not yet recruiting

  • Nordmøre and Romsdal Hospital - Kristiansund

    Kristiansund, Norway · Not yet recruiting

  • Levanger hospital

    Levanger, Norway · Not yet recruiting

  • Nordmøre and Romsdal Hospital - Molde

    Molde, Norway · Not yet recruiting

  • Akershus University Hospital (AHUS)

    Nordbyhagen, Norway · Not yet recruiting

  • Diakonhjemmet hospital

    Oslo, Norway · Not yet recruiting

  • Lovisenberg Diaconal Hospital

    Oslo, Norway · Not yet recruiting

  • Oslo Myeloma Center, Oslo University Hospital

    Oslo, Norway · Not yet recruiting

  • Telemark Hospital Trust

    Skien, Norway · Not yet recruiting

  • Stavanger University hospital

    Stavanger, Norway · Not yet recruiting

  • Vestfold Hospital Trust

    Tønsberg, Norway · Not yet recruiting

  • University hospital of North Norway

    Tromsø, Norway · Not yet recruiting

  • St. Olavs hospital HF

    Trondheim, Norway · Recruiting

  • Volda hospital

    Volda, Norway · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.